Strategies To Win Breakthrough Designation In Rare Disease Programs

By Mwango Kashoki, M.D., M.P.H., Senior Vice President, Global Head of Regulatory Strategy

Breakthrough therapies don’t just move fast—they can reset the entire pace of rare disease innovation. Breakthrough Therapy Designation (BTD) is one of the most powerful tools available to sponsors, offering early, hands‑on regulatory engagement and the opportunity to accelerate development in ways traditional pathways can’t match.

Winning BTD demands more than promising signals. Sponsors must show compelling, clinically meaningful improvement, package early‑phase data into a crisp narrative, and approach regulators at the optimal inflection point, when momentum and unmet need are most clearly demonstrated. Early alignment on endpoints, patient populations, and evidence expectations can help turn emerging data into a designation‑ready submission.

With sharp timing and a strategic evidence plan, sponsors can dramatically elevate their chances of securing BTD. When executed well, breakthrough designation becomes a force multiplier—reducing uncertainty, speeding decisions, and getting transformative therapies to patients who need them sooner.